Ultime notizie per Delta Apparel (OTC:DLAPQ) Azioni

Delta Apparel Inc together with its subsidiaries is an international apparel design, marketing, manufacturing, and sourcing company. It operates its business in two distinct segments: Delta Group and Salt Life Group. The company offers a diverse portfolio of lifestyle basics and branded activewear apparel, headwear, and related accessory products. It specializes in selling casual and athletic products through distribution channels and distribution tiers, including specialty stores, boutiques, department stores, mid and mass channels, e-retailers, and the U.S. military. It also offers its products to consumers on its websites and in its retail stores. The company derives the maximum revenue from the wholesale of goods through the Delta Group in the United States.

DELTA APPAREL INC by Delta Apparel Company

Delta Apparel Inc

Mizuho analyst Ann Hynes maintains CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) with a Outperform and raises the price target from $70 to $76.

News

Price Target

Analyst Ratings

Mizuho Maintains Outperform on CVS Health, Raises Price Target to $76

Needham analyst Gil Blum reiterates Absci (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABSI#NASDAQ">ABSI</a>) with a Buy and maintains $9 price target.

Reiteration

ABSI

Needham Reiterates Buy on Absci, Maintains $9 Price Target

Xi Jinping&#8216;s China has unveiled a significant hike in retaliatory tariffs on U.S. products, intensifying the ongoing trade war between the world&#8217;s two biggest economies.
What Happened: On Wednesday, China declared that it will raise its reciprocal tariffs on U.S. goods to 84% from the previous 34% from April 10, <a href="https://www.scmp.com/economy/china-economy/article/3305873/china-fires-back-stern-rebuke-trumps-tariff-escalation?module=top_story&amp;pgtype=homepage">reported</a> the South China Morning Post. 
This move comes in the wake of an intensifying trade conflict between the U.S. and China. This comes after the latest U.S. tariff hike — which brings levies on Chinese goods to more than 100% — took effect at the start of April 9.
In response to the new U.S. tariffs, the Ministry of Commerce not only filed a complaint with the World Trade Organization but also added six American companies to its unreliable-entity list. Additionally, it imposed export controls on 12 U.S. firms, prohibiting Chinese companies from supplying them with dual-use items—products that can serve both civilian and military purposes.
"China will firmly defend its interests, multilateral trade system and international economic order," stated the Chinese finance ministry online.
SEE ALSO:&nbsp;<a href="https://benzinga.com/markets/25/04/44706492/trump-predicts-tremendous-thundering-landslide-in-2026-midterms-says-tariffs-will-help-republicans-win-bi" target="_blank" rel="noreferrer noopener">Trump Predicts &#8216;Tremendous, Thundering Landslide&#8217; In 2026 Midterms, Says Tariffs Will Help Republicans Win Big</a>
Why It Matters: This announcement comes on the heels of President Donald Trump&#8216;s <a href="https://www.benzinga.com/markets/equities/25/04/44704005/trumps-104-tariff-on-chinese-imports-sends-stock-futures-plunging-dow-falls-over-500-points">104% tariff on Chinese imports</a>, which sent stock futures plunging and major indexes to significant lows. 
Despite the escalating trade war, many U.S. companies <a href="https://www.benzinga.com/news/global/25/04/44700937/us-companies-stick-with-china-as-trump-tariffs-take-effect-report">have chosen to stick </a>with their operations in China, viewing it as a strategic value. A report commissioned by the U.S. Chamber of Commerce Foundation revealed that a majority of surveyed firms still see value in maintaining or expanding their presence in China, even as they increasingly view it as their biggest geopolitical risk.
This escalating trade conflict is likely to have far-reaching implications on the global economy, and all eyes are on how this situation will unfold in the coming days.
During the U.S. premarket session, U.S.-listed Chinese stocks traded mixed. Baidu Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>) and Nio Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) were in the red, while Xpeng Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>) and Li Auto Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>) saw modest gains.
<ul>
<li>READ MORE:&nbsp;<a href="https://benzinga.com/markets/cryptocurrency/25/04/44699720/bitcoin-ethereum-xrp-dogecoin-extend-losses-as-white-house-hammers-chinese-goods-with-104-tariff" target="_blank" rel="noreferrer noopener">Bitcoin, Ethereum, XRP, Dogecoin Extend Losses As White House Hammers Chinese Goods With 104% Tariff &#8211; Benzinga</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Markets

BIDU

XPEV

Xi Jinping Hits Back: China Raises Tariffs On US Goods To 84%, Doubling Down On Trade War

Mizuho analyst Ann Hynes maintains Ardent Health Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARDT#NYSE">ARDT</a>) with a Outperform and lowers the price target from $19 to $18.

ARDT

Mizuho Maintains Outperform on Ardent Health Partners, Lowers Price Target to $18

WIIM

PHIO

Phio Pharmaceuticals shares are trading higher after the company announced its Safety Monitoring Committee recommended dose escalation in the Phase 1b trial of PH-762.

Needham analyst Serge Belanger reiterates Cormedix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>) with a Buy and maintains $12 price target.

CRMD

Needham Reiterates Buy on Cormedix, Maintains $12 Price Target

Mizuho analyst James Lee maintains Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) with a Outperform and lowers the price target from $285 to $255.

AMZN

Mizuho Maintains Outperform on Amazon.com, Lowers Price Target to $255

Phio's Phase 1b clinical trial is a multi-center, dose-escalating trial designed to evaluate the safety and tolerability of neoadjuvant use of intratumoral PH-762 in cutaneous squamous cell carcinoma, melanoma, or Merkel cell carcinoma. This trial assesses the tumor response and determines the recommended dose for further study of PH-762. In the third cohort of this trial, three patients with cutaneous squamous cell carcinoma were enrolled. For these patients, injections were well tolerated with no serious adverse events and there were no dose-limiting toxicities. Pathology results related to efficacy of PH-762 in the third cohort are forthcoming.

Biotech

Health Care

General

The Safety Monitoring Committee Recommended Dose Escalation In Phio Pharmaceuticals' Phase 1b Trial For The Company's Lead Product Candidate, PH-762

BTDR

Bitdeer Technologies Reported Self-mined Bitcoin Of 114 (Vs. 294 A Year Ago), Total Hash Rate Under Management (EH/S) Of 24.2 In March 2025 Vs. 22.5 In March 2024

Mizuho analyst James Lee maintains Alphabet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) with a Outperform and lowers the price target from $230 to $205.

GOOGL

Mizuho Maintains Outperform on Alphabet, Lowers Price Target to $205

<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="900" height="600" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/09064759/SDEW.png" alt="" class="wp-image-10060" style="width:920px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/09064759/SDEW.png 900w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/09064759/SDEW-300x200.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/09064759/SDEW-768x512.png 768w" sizes="(max-width: 900px) 100vw, 900px" /></figure>
As smart driving features trickle down to budget cars, the balance of power is shifting to automakers and away from their technology suppliers
China's autonomous driving industry is undergoing a major power shift. As "smart driving equality" emerges as the dominant narrative, a quiet revolution is underway — transitioning the industry from one limited to luxury cars to one with mainstream capabilities across the entire automotive sector.
Major Chinese automakers like&nbsp;BYD&nbsp;(1211.HK; 002594.SZ),&nbsp;NIO&nbsp;(NIO.US; 9866.HK),&nbsp;XPeng&nbsp;(XPEV.US; 9868.HK) and AITO are no longer confining their advanced autonomous driving functions to flagship models. To the contrary, features like navigation on autopilot (NOA), automated parking and city pilot are being rapidly rolled out across mid- and lower-end models priced below 200,000 yuan ($27,400).
While not the first to do so, BYD's launch of its high-level DiPilot system on models costing below 100,000 yuan at the beginning of this year marked a turning point—confirming that the era of smart driving equality had truly arrived.
"In the automotive sector, we believe that full-scale intelligentization will strengthen the global leadership of Chinese brands," said BYD founder Wang Chuanfu. "This is a show of confidence from China's auto industry, and reflects the confidence of Chinese technology."
Historically, high-level autonomous driving was a high-margin business, relying on premium hardware like LiDAR, HD cameras, domain controllers, and powerful chips — typically reserved for luxury models. But as smart driving becomes more accessible, automakers are increasingly taking control of core technologies to protect their profit margins.
BYD's DiPilot, XPeng's XNGP,&nbsp;Li Auto's (LI.US; 2015.HK) AD Max, and Huawei's ADS 2.0 illustrate this shift. Automakers are building their own algorithm teams, mapping systems, and even managing data annotation and simulation training in-house. As a result, upstream suppliers are being pushed to the sidelines, downgraded from solution providers to low-margin parts vendors.
Suppliers like&nbsp;RoboSense&nbsp;(2498.HK) are now offering low-cost solid-state LiDAR and modular solutions.&nbsp;Hesai&nbsp;(HSAI.US) is co-developing customized sensors with automakers.
For suppliers, this is a fight for survival. Without core technologies or the ability to scale, many small and mid-sized vendors face an uphill battle, and are surviving only with razor-thin margins. Only those with system integration, algorithm coordination, and global delivery capabilities are likely to endure.
Behind the push to make advanced autonomous driving available to all lies a quiet industry reshuffling and a redistribution of power. The real winners will be those companies that can not only manufacture vehicles but also master the soul of intelligent driving.

Equities

Travel

Opinion

Tech

Smart Driving Equality: A Battle For Control Of An Emerging Industry

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Genmab (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GMAB#NASDAQ">GMAB</a>) with a Buy and lowers the price target from $50 to $37.

GMAB

HC Wainwright & Co. Reiterates Buy on Genmab, Lowers Price Target to $37

On Wednesday, the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for a new patent related to Anixa Biosciences, Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIX#NASDAQ">ANIX</a>) breast <a target="_blank" href="https://www.benzinga.com/exclusives" rel="noreferrer noopener">cancer vaccine technology</a>.
Cleveland Clinic has exclusively licensed the patent and others related to this technology to Anixa Biosciences. The patent will expand the scope of immunogenic compositions utilized in Anixa's breast cancer vaccine.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44471206/exclusive-anixa-biosciences-inks-letter-of-intent-with-austria-based-verdi-solutions-to-develop-ai-guided-personalized-cancer-vaccines" rel="noreferrer noopener">EXCLUSIVE: Anixa Biosciences Inks Letter of Intent with Austria-Based VERDI Solutions To Develop AI-Guided Personalized Cancer Vaccines</a>
This newly allowed patent covers methods of immunizing patients against breast cancer by administering an immunogenic composition containing the human α-lactalbumin protein, a protein typically found in breast tissue during lactation but also expressed in certain breast cancers.
Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences, stated, "This patent strengthens our intellectual property portfolio and highlights the novelty of our breast cancer vaccine. Our intellectual property portfolio includes multiple issued and pending patents in the U.S. and international jurisdictions."
In March, the USPTO issued a Notice of Allowance for a key patent application covering&nbsp;Anixa Biosciences <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44455186/exclusive-anixa-biosciences-poised-to-receive-us-patent-for-ovarian-cancer-vaccine" rel="noreferrer noopener">ovarian cancer vaccine technology</a>.
The patent includes broad claims related to methods of eliciting an immune response targeting the Anti-Mullerian Hormone Receptor, Type II (AMHR2), a target for ovarian cancer prevention and treatment.
Anixa's ovarian cancer vaccine is being developed in collaboration with Cleveland Clinic and the National Cancer Institute.
The allowed claims include methods of administering an immunogenic composition comprising a nucleic acid encoding the AMHR2 polypeptide, specifically the extracellular domain of human AMHR2, to elicit an AMHR2-specific immune response.
Price Action: ANIX stock closed at $2.38 on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44698946/cell-therapy-maker-legend-biotech-an-attractive-opportunity-in-unpredictable-times-analyst" target="_blank" rel="noreferrer noopener">Cell Therapy Maker Legend Biotech Is An ‘Attractive Opportunity' Due To No Material Tariff Exposure: Analyst</a></li>
</ul>

Market-Moving Exclusives

Exclusives

ANIX

EXCLUSIVE: Anixa Biosciences Receives Key US Patent Nod For Breast Cancer Vaccine Patent

EXCLUSIVE: Anixa Biosciences Tells Benzinga 'Patent Broadens Immunogenic Compositions for Preventive Vaccine Approach'

EXCLUSIVE: Anixa Biosciences Tells Benzinga Co. Receives Notice Of Allowance From US Patent And Trademark Office For Patent Covering Breast Cancer Vaccine Technology

Morgan Stanley analyst Vincent Sinisi maintains RPM Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RPM#NYSE">RPM</a>) with a Equal-Weight and lowers the price target from $125 to $113.

Morgan Stanley Maintains Equal-Weight on RPM Intl, Lowers Price Target to $113

Morgan Stanley analyst Alex Straton maintains Levi Strauss (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEVI#NYSE">LEVI</a>) with a Equal-Weight and lowers the price target from $17 to $16.

LEVI

Morgan Stanley Maintains Equal-Weight on Levi Strauss, Lowers Price Target to $16

HC Wainwright &amp; Co. analyst Yi Chen initiates coverage on Bionano Genomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNGO#NASDAQ">BNGO</a>) with a Buy rating and announces Price Target of $10.

Initiation

BNGO

HC Wainwright & Co. Initiates Coverage On Bionano Genomics with Buy Rating, Announces Price Target of $10

21Shares, one of the largest issuers of <a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43742669/a-dogecoin-etf-approval-in-2025-is-becoming-increasingly-likely-polymarket-traders-speculate">crypto exchange-traded products</a> (ETPs), has officially launched the 21Shares Dogecoin ETP, the first Dogecoin-backed product endorsed by the Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) Foundation.
What Happened: The product went live today, with <a href="https://www.21shares.com/en-eu/product/doge">listing</a> on Swiss exchanges under the ticker DOGE.
The Dogecoin ETP offers exposure to the sixth-largest cryptocurrency by market capitalization, which closed 2024 valued at $46 billion—on par with legacy brands like General Motors.
The ETP enables both institutional and retail investors to gain direct access to Dogecoin through their bank or brokerage accounts, without needing to handle digital wallets or private keys.
"In partnership with House of Doge, we're excited to introduce the only Dogecoin ETP endorsed by the Dogecoin Foundation," 21Shares announced in a <a href="https://x.com/21Shares/status/1909876206020837776">statement</a> on social media. "Here's to the meme that made it."
The product has an annual fee of 2.5%, a net asset value of $5.00 per unit, and is not currently eligible for lending. 
The initial assets under management total $1.2 million, with 240,000 securities outstanding.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44703305/bitcoin-is-a-more-liquid-and-higher-volatility-version-of-gold-bernstein">Bitcoin Is A &#8216;More Liquid And Higher Volatility Version Of Gold&#8217;: Bernstein</a>
Why It Matters: Dogecoin, launched in 2013 as a lighthearted take on cryptocurrencies inspired by the viral &#8220;Doge&#8221; meme, has since grown into a recognized global payments solution.
The currency's accessibility and loyal user base have helped transform it from a cultural phenomenon into a practical gateway for crypto adoption.
21Shares' listing provides investors with a structured and regulated way to gain exposure to Dogecoin without having to directly purchase or manage the token via a crypto wallet. 
This approach is increasingly popular among traditional investors looking for simplified access to digital assets.
Dogecoin's growth has also been propelled by a strong, socially-driven community known for charitable initiatives and open participation. 
Community-led campaigns such as Doge4Water, which raised funds in 2014 to provide clean water infrastructure in Kenya, reflect the grassroots ethos behind the token.
The 21Shares Dogecoin ETP launch marks another step in the maturation of meme-driven cryptocurrencies into investable financial instruments, as regulators and traditional institutions respond to continued demand for accessible crypto investment vehicles.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44696653/how-bitcoin-will-go-from-65000-to-225000-in-2025">How Bitcoin Will Go From $65,000 To $225,000 In 2025</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$DOGE

MSFT

21Shares Launches Dogecoin Fund Backed By Dogecoin Foundation

Morgan Stanley analyst Brian Wilczynski initiates coverage on Atlantic Union Bankshares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AUB#NYSE">AUB</a>) with a Equal-Weight rating and announces Price Target of $32.

Comments

Delta Apparel

Notizie

Ultime notizie per Delta Apparel (OTC:DLAPQ) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO